Skyline funds Lief Labs

Skyline Global Partners has made an investment in Lief Labs, a maker of dietary supplements.

Skyline Global Partners has made an investment in Lief Labs, a maker of dietary supplements. No financial terms were disclosed.

PRESS RELEASE

Skyline Global Partners LLC is pleased to announce the close of an equity investment in Lief Labs (“Lief” or the “Company”). Financial terms of the transaction were not disclosed.
Lief Labs is a premier formulation and product development innovator and manufacturer of dietary supplements. The Company’s in-house Product Development and R&D team creates the best tasting and most cutting-edge formulations of supplements. Lief also houses over 220,000 sq ft of new and fully renovated, full-service, state-of-the-art, Current Good Manufacturing Practice (cGMP) manufacturing facility, which includes an in-house analytical testing lab and a microbiology lab, and offers custom solutions for a multitude of supplement categories. The Company collaborates with entrepreneurial firms to help them build premier brands. Lief’s turnkey solutions allow it to engage in seamless partnerships that help brands with scalability and sustainable growth. The Company was founded in 2008 and is based in Valencia, CA.

Our investment provided liquidity for shareholders and growth capital for the business. More information on Lief Labs may be found at: www.lieflabs.com.

About Skyline Global Partners
Skyline Global Partners LLC is a lower middle market private equity firm based in Chicago, Illinois. We focus on buyouts and growth equity investments on a control or minority ownership basis in the United States and Canada. Skyline targets companies in the healthcare, manufacturing, distribution, business services, software/SaaS & eCommerce, consumer products, and food/beverage/agriculture sectors.